Russia
· Delayed Price · Currency is RUB Artgen Biotech PJSC Statistics
Total Valuation
Artgen Biotech PJSC has a market cap or net worth of RUB 4.29 billion. The enterprise value is 4.94 billion.
| Market Cap | 4.29B |
| Enterprise Value | 4.94B |
Important Dates
The last earnings date was Wednesday, September 11, 2024.
| Earnings Date | Sep 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Artgen Biotech PJSC has 71.99 million shares outstanding. The number of shares has increased by 0.70% in one year.
| Shares Outstanding | 71.99M |
| Shares Change (YoY) | +0.70% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 46.46% |
| Owned by Institutions (%) | 0.41% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 24.90.
| PE Ratio | 24.90 |
| Forward PE | n/a |
| PS Ratio | 3.67 |
| PB Ratio | 12.70 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.73, with an EV/FCF ratio of 16.57.
| EV / Earnings | 22.43 |
| EV / Sales | 3.31 |
| EV / EBITDA | 12.73 |
| EV / EBIT | 15.36 |
| EV / FCF | 16.57 |
Financial Position
The company has a current ratio of 1.88, with a Debt / Equity ratio of 82.78.
| Current Ratio | 1.88 |
| Quick Ratio | 0.99 |
| Debt / Equity | 82.78 |
| Debt / EBITDA | 1.95 |
| Debt / FCF | 2.65 |
| Interest Coverage | 6.43 |
Financial Efficiency
Return on equity (ROE) is 29.67% and return on invested capital (ROIC) is 12.56%.
| Return on Equity (ROE) | 29.67% |
| Return on Assets (ROA) | 8.70% |
| Return on Capital (ROIC) | 12.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.98 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.68% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +56.68% |
| 50-Day Moving Average | 66.85 |
| 200-Day Moving Average | 91.44 |
| Relative Strength Index (RSI) | 40.78 |
| Average Volume (20 Days) | 234,009 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Artgen Biotech PJSC had revenue of RUB 1.49 billion and earned 220.07 million in profits. Earnings per share was 2.39.
| Revenue | 1.49B |
| Gross Profit | 1.03B |
| Operating Income | 338.38M |
| Pretax Income | 269.26M |
| Net Income | 220.07M |
| EBITDA | 382.98M |
| EBIT | 338.38M |
| Earnings Per Share (EPS) | 2.39 |
Balance Sheet
The company has 370.13 million in cash and 789.60 million in debt, giving a net cash position of -419.47 million or -5.83 per share.
| Cash & Cash Equivalents | 370.13M |
| Total Debt | 789.60M |
| Net Cash | -419.47M |
| Net Cash Per Share | -5.83 |
| Equity (Book Value) | 953.87M |
| Book Value Per Share | 4.69 |
| Working Capital | 475.69M |
Cash Flow
In the last 12 months, operating cash flow was 495.43 million and capital expenditures -197.47 million, giving a free cash flow of 297.96 million.
| Operating Cash Flow | 495.43M |
| Capital Expenditures | -197.47M |
| Free Cash Flow | 297.96M |
| FCF Per Share | 4.14 |
Margins
Gross margin is 68.86%, with operating and profit margins of 22.67% and 14.74%.
| Gross Margin | 68.86% |
| Operating Margin | 22.67% |
| Pretax Margin | 18.04% |
| Profit Margin | 14.74% |
| EBITDA Margin | 25.66% |
| EBIT Margin | 22.67% |
| FCF Margin | 19.96% |
Dividends & Yields
Artgen Biotech PJSC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.70% |
| Shareholder Yield | -0.70% |
| Earnings Yield | 4.02% |
| FCF Yield | 6.95% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |